Angiodynamics announces first patient enrolled in recover-av clinical trial evaluating alphavac f1885 system for treatment of acute pulmonary embolism

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life, today announced the first patient has been enrolled in the recover-av clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the alphavac multipurpose mechanical aspiration (mma) f1885 system in t.
ANGO Ratings Summary
ANGO Quant Ranking